Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 3

Terminated

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Cytarabine
Other: Placebo
Drug: Idasanutlin

First Posted Date: 2015-09-09

Last Posted Date: 2022-01-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 447

Registration Number: NCT02545283

Locations: 🇫🇷
Hopital Claude Huriez; Hematologie, Lille, France
🇫🇷
Institut J Paoli I Calmettes; Onco Hematologie 2, Marseille, France
🇫🇷
Hopital Saint Louis; Oncologie Medicale, Paris, France

and more 79 locations

Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population

Withdrawn

Conditions: Metastatic Colorectal Cancer

Interventions: Other: No intervention

First Posted Date: 2015-09-07

Last Posted Date: 2017-09-13

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT02542436

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: Atezolizumab

First Posted Date: 2015-09-04

Last Posted Date: 2020-02-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 87

Registration Number: NCT02541604

Locations: 🇨🇭
Universitäts-Kinderspital; Abteilung für Onkologie, Zürich, Switzerland
🇮🇹
Azienda Ospedaliera di Padova; Clinica di Onco-ematologia pediatrica, Padova, Veneto, Italy
🇪🇸
Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona, Spain

and more 27 locations

Observational Study of MIRCERA in Users of Self-Application and Multidose Systems

Completed

Conditions: Renal Anemia of Chronic Kidney Disease

Interventions: Device: MIRCERA

First Posted Date: 2015-09-03

Last Posted Date: 2015-12-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 240

Registration Number: NCT02540213

An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant

Completed

Conditions: Anemia, Kidney Transplantation

Interventions: Drug: Methoxy-polyethyleneglycol epoetin beta

First Posted Date: 2015-09-02

Last Posted Date: 2017-06-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 290

Registration Number: NCT02538107

Locations: 🇩🇪
Klinikum Hann. Münden, Nephrologisches Zentrum Niedersachsen, Hann. Münden, Germany

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: FP
Drug: LABA
Drug: LTRA
Drug: LAMA
Drug: Theophylline
Drug: Oral Corticosteroids

First Posted Date: 2015-09-02

Last Posted Date: 2019-04-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 483

Registration Number: NCT02537691

Locations: 🇱🇻
Riga 1st hospital, outpatient clinic Bruninieks, Riga, Latvia
🇱🇻
Clinical Hospital Gailezers; Dept of Pulmonology, Riga, Latvia
🇱🇻
Latvian University postgraduate institute, Riga, Latvia

and more 97 locations

Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea

Completed

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

First Posted Date: 2015-09-02

Last Posted Date: 2017-07-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1695

Registration Number: NCT02538562

Locations: 🇰🇷
Chonbuk National Uni Hospital, Jeollabuk-do, Korea, Republic of
🇰🇷
Inje university Haeundae Paik Hospital, Busan, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

and more 11 locations

Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: Rituximab

First Posted Date: 2015-09-01

Last Posted Date: 2023-04-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 505

Registration Number: NCT02536664

An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants

Completed

Conditions: Breast Cancer

First Posted Date: 2015-08-28

Last Posted Date: 2017-04-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 580

Registration Number: NCT02535026

A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2015-08-27

Last Posted Date: 2018-02-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT02534311

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy